2 Information about pembrolizumab

2 Information about pembrolizumab

Marketing authorisation indication

Pembrolizumab (Keytruda, Merck Sharp & Dohme) has a marketing authorisation for 'the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy'.

Dosage in the marketing authorisation

200 mg by intravenous infusion every 3 weeks until disease progression or unacceptable toxicity.


£2,630 per 100 mg vial (excluding VAT; company submission).

As part of the managed access agreement, the company has a commercial access agreement with NHS England. This makes pembrolizumab available at a reduced cost. The financial terms of the agreement are commercial in confidence.

  • National Institute for Health and Care Excellence (NICE)